EWA vs IBB
iShares MSCI Australia ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.50% for EWA.
- • EWA pays a higher dividend yield (2.88%).
Side-by-side metrics
| Metric | EWA | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.50% | 0.44% |
Dividend yield Trailing 12-month yield. | 2.88% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $1.25B | $11.50B |
YTD return | 14.89% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.94 | 0.60 |
P/E ratio | 20.32 | 25.48 |
Last price | $29.40 | $217.75 |
Inception | — | — |
Issuer | iShares | iShares |
EWA top holdings
| BHP.AX | BHP Group Ltd | 14.33% |
| CBA.AX | Commonwealth Bank of Australia | 13.67% |
| NAB.AX | National Australia Bank Ltd | 6.34% |
| WBC.AX | Westpac Banking Corp | 6.17% |
| ANZ.AX | ANZ Group Holdings Ltd | 6.03% |
| CSL.AX | CSL Ltd | 4.71% |
| MQG.AX | Macquarie Group Ltd | 4.51% |
| WES.AX | Wesfarmers Ltd | 4.27% |
| WDS.AX | Woodside Energy Group Ltd | 3.10% |
| RIO.AX | Rio Tinto Ltd | 2.68% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About EWA
EWA (iShares MSCI Australia ETF) is Australian large and mid-cap equities. Managed by iShares, the fund carries $1.2B in assets under management, an expense ratio of 0.50%, a dividend yield of 2.88%. Its largest holding is BHP Group Ltd (BHP.AX), which represents 14.3% of the portfolio. Real Estate is the fund's largest sector exposure at 4.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.